Gain Therapeutics (GANX) Return on Capital Employed (2021 - 2025)
Historic Return on Capital Employed for Gain Therapeutics (GANX) over the last 5 years, with Q3 2025 value amounting to 2.82%.
- Gain Therapeutics' Return on Capital Employed fell 10600.0% to 2.82% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.82%, marking a year-over-year decrease of 10600.0%. This contributed to the annual value of 1.78% for FY2024, which is 4200.0% down from last year.
- As of Q3 2025, Gain Therapeutics' Return on Capital Employed stood at 2.82%, which was down 10600.0% from 3.12% recorded in Q2 2025.
- In the past 5 years, Gain Therapeutics' Return on Capital Employed registered a high of 0.19% during Q2 2021, and its lowest value of 3.12% during Q2 2025.
- In the last 5 years, Gain Therapeutics' Return on Capital Employed had a median value of 1.57% in 2023 and averaged 1.42%.
- Its Return on Capital Employed has fluctuated over the past 5 years, first tumbled by -15100bps in 2023, then soared by 3900bps in 2024.
- Gain Therapeutics' Return on Capital Employed (Quarter) stood at 0.36% in 2021, then plummeted by -122bps to 0.8% in 2022, then tumbled by -142bps to 1.95% in 2023, then dropped by -12bps to 2.18% in 2024, then fell by -29bps to 2.82% in 2025.
- Its last three reported values are 2.82% in Q3 2025, 3.12% for Q2 2025, and 2.97% during Q1 2025.